Apremilast

Patients with genital psoriasis had a clinically significant response to apremilast treatment, according to phase 3 trial results.

Recently published in the British Journal of Dermatology, AbbVie’s phase 4 head-to-head study shows risankizumab demonstrates superiority over apremilast for the treatment of adults with moderate plaque psoriasis.

At the 2023 European Congress of Rheumatology, Amgen presented study results evaluating the use of Otezla for the treatment of psoriatic arthritis, according to a company press release.

NEW ORLEANS — Apremilast 30 mg significantly improved genital psoriasis severity and quality of life compared with placebo in the first trial to study an oral treatment for this indication, according to a presentation here.

Apremilast may be an efficacious and safe treatment option for patients with recalcitrant cutaneous dermatomyositis, according to a study.

Patients with psoriasis taking apremilast saw a 5% to 6% decrease in subcutaneous and visceral adiposity, indicating that the drug may benefit cardiometabolic health, according to a study.

BOSTON — A phase 2 trial found Japanese patients with palmoplantar pustulosis treated with apremilast showed significant and early improvement, according to a poster presented at the American Academy of Dermatology Annual Meeting.

BOSTON — Psoriasis patients treated with apremilast saw a reduction in subcutaneous and visceral fat, indicating a possible decline in cardiometabolic risk, according to a presentation at the American Academy of Dermatology Annual Meeting.

The FDA has approved Otezla for the treatment of patients with plaque psoriasis of all severity levels, according to a company press release.

Overall psoriasis severity and scalp psoriasis, as well as itch and quality of life, were improved in patients who used apremilast, according to a phase 3 study.